

Co-infection of Covid -19 patient with *A. baumannii* in Iraqi patientsMaha E. Zidan¹, Hiba M. Nasir² and Jaleel Samanje^{*3}^(1,2,3) College of Health and Medical Techniques, Middle Technical University (MTU) / Baghdad-Iraq.Correspondence author: E-Mail(*): Jaleel.najah@mtu.edu.iq**Abstract**

Acinetobacters.baumannii is an opportunistic pathogens have a high incidence through immunocompromised individuals, especially those who have experienced prolonged hospital stay. To investigate the prevalence of antibiotic resistance genes of *A. baumannii* in Iraqi Covid -19 patients. Fifty clinical isolates out of (86) isolates of *A. baumannii* were isolated from patients attacked with Covid-19 from different clinical sources and from different hospitals. All the clinical samples primarily were cultured on Blood, MacConkey agar. For differentiation of *A. baumannii*, the clinical samples were also streaked on Drigalski Lactose agar medium. Suspected colonies were confirmed by VITEK-2 system. Co-infected *A. baumannii* sample with Covid -19 were subjected to molecular detection with 16srRNA and bla NDM-2 gene. Results of this study found that (50) isolates of *A. baumannii* with multidrug resistant (MDR) and (XDR) properties out of (86) isolates of *A. baumannii* were diagnosed molecularly by 16srRNA and identified 32 (64%) positive samples out of (50) isolates. Also results observed that the 21 (65.6%) sample out of 32 (positive sample for 16sRNA) have COVID-19 infection. Co-infected patients were more in male than female groups (76.2% , 23.8%) respectively. Also results found that antibiotic resistant gene (*bla*NDM-2) for *A. baumannii* associated with covid-19 were 15 (71.4%) in patients with covid -19. In conclusion the patients attacked with both Covid-19 and *A. baumannii* are at high risk of longer stay in hospital and potentially death also this study concluded the prevalence of antibiotic resistance among co-infected patients especially with amikacin and tetracycline antibiotics.

Keywords: *A. baumannii*, COVID-19, *bla*NDM-2, 16 SrRNA .

دراسة عدوى COVID-19 المصاحبة للإصابة بالراكدة البومانية لبعض المرضى العراقيين

مها اسماعيل زيدان¹، هبة منصور ناصر² و أ.م.د. جليل سمنجي³

الخلاصة

A. baumannii الراكدة البومانية من مسببات الأمراض الانتهازية ، نسبتها عالية في الأفراد الذين يعانون من نقص المناعة، وخاصة أولئك الذين عانوا من الإقامة الطويلة في المستشفى. ولمعرفة انتشار جينات مقاومة للمضادات الحيوية لبكتريا *A. baumannii* لمرضى كوفيد-19 العراقيين. تم عزل خمسين عينة سريرية من أصل (86) عزلة من *A. baumannii* من المرضى المصابين بفيروس Covid-19 من مصادر سريرية مختلفة ومن مختلف المستشفيات. تم استنبات جميع العينات السريرية بشكل

أساسي على أجار الدم ، MacConkey. من أجل تمييز *A. baumannii* ، تم تخطيطها على وسط Drigalski Lactose agar. وتم التأكد من المستعمرات المشتبه بها بواسطة نظام VITEK-2. تم إخضاع عينات *A. baumannii* من المرضى المصابين بـ Covid-19 للكشف الجزيئي باستخدام جين 16sRNA و blaNDM-2. أظهرت نتائج هذه الدراسة أنه تم تشخيص (50) عذلة من *A. baumannii* ذات المقاومة للأدوية المتعددة (MDR) و (XDR) من أصل (86) عذلة من *A. baumannii* بواسطة 16 sRNA وتم تشخيص 32 (64%) عينة إيجابية من أصل (50) عذلة. كما لاحظت النتائج أن 21 (65.6%) عينة من 32 (عينة إيجابية لـ 16sRNA) مصابون بعدوى covid-19. كان المرضى المصابون بالعدوى المصاحبة أكثر في الذكور مما في النساء (76.2% ، 23.8% على التوالي). أيضًا وجدت النتيجة أن الجين المقاوم للمضادات الحيوية (blaNDM-2) لـ *A. baumannii* المرتبط بـ covid-2 كان 15 (71.4%) في المرضى المصابين بـ covid-19. المرضى المصابين بعدوى الراكدة اليومية وعدوى فايروس كورونا سويًا يكون معرضين لخطر الرقود في المستشفيات لفترة طويلة وكذلك معرضين لخطر الموت، نتائج هذه الدراسة اوضحت انتشار مقاومة بكتريا الراكدة في الاشخاص المصابين بفايروس كورونا للمضادات الحيوية وخصوصا مضاد التتراسايكلين والاميكاسين

الكلمات المفتاحية : الرنا الريباسي 16S، الراكدة البومانية، جين بلاانديم، فايروس كورونا.

Introductions

A. baumannii is a grams-negative (G-ve), non-lactose fermenting organism that was increasingly recognized as a major pathogens causing nosocomials infections including ventilator-associated pneumonia, bacteremia, urinary tracts infection, meningitis and wound infections particularly in patients admitted to intensives care units (ICU) [1]. *Acinetobacte. baumannii* can alsoe cause community-acquireds infections, which are encountereds mainly in tropicals Australia and Southeast Asias [2]. For Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hospitals-acquired infections(HAI) was defined as secondary infection occurring more than 48 hours after hospitalization. Pneumoniase occurings 48 hours or more after hospitalization or endotracheal intubations were defined as hospitals-acquirede pneumonia (HAP) and ventilators-associated pneumoniae(VAP) [3]. (SARSCoV-2) infection can produce severesand critical respiratory failure required septic shock, mechanical ventilation, or others organ dysfunction or loss necessitates intensives care treatment [4]. The carbapenems resistance occurred in *A. baumannii* shortly later the introduction and therapeutic use of carbapenems and disseminated globally, the management of patientse with coronavirus disease 2019 (COVIDs-19) will be greatly problematic especiallys when co-infecteds with antibiotic resistant bacteria commonly distributede in hospitals [5]. During the COVIDs-19 pandemics, co-infection with *A. baumannii* secondarysof SARSCoV-2 infections occurs. An isolates with (OXAe-23) genes has been responsables for an outbreaks in COVIDs-19 ICUs of a tertiarys Japanese hospital [6]. Incidences of secondary infectionse(mostly lowers respiratorys tracts infectionse) attributeds to *A. baumannii* have been reporteds to be as high as (1%) of hospitalized COVIDs-19 patients in an Italians hospital (6). A

recent studies from a French intensive care treatment (ICU) calculated co-infection with *A. baumannii* at (1.1%) (1 out of 92; susceptible to third generation cephalosporins) in severe SARS-CoV-2 pneumonia patients [7].

Recently, the bla_{NDM-2} variants (Pro to Ala substitutions at positions-28) was described, this allele was first found in a multidrug-resistant (MDR) *A. baumannii* strain isolated from a German patient having previously been hospitalized in Egypt. While a subsequent one was isolated in Israel [8]. The presence of super-infections in the lower respiratory tracts of patients with COVID-19 due to that *A. baumannii* area resistant to the extended-spectrum antibiotics commonly used for the treatment of life-threatening bacterial diseases, especially in ICU patients. Secondary bacterial infections may develop during or following COVIDs-19 and thus they are an undeniable fact, as a result of severe pandemic conditions, it was not possible to have a negative control group without COVIDs-19 in our ICUs simultaneously [9]. Due to the previous information so this study was aimed to, detect the Co-infection of *A. baumannii* with COVID-19 infections and related antibiotic resistant gene in these patients.

Material and method

Bacterial identification

Fifty isolates of *A. baumannii* out of (86) patients with COVID-19 patients in both sexes. The collected clinical sample from different patient's sources (burns, sputum, wound swabs) were subjected for streaking methods directly on Blood agar and MacConkey agar. Further identification by morphological characteristics, biochemical, and VITEK-2 System. By using bacterial suspension then the inoculated card has been passed through a mechanism carousel incubator according to [10].

Antibiotic resistance

Antibiotic sensitivity of *A. baumannii* isolates by Kirby-Bauer disk diffusion method were applied to study the effect of seven types of antibiotic including: Amikacin, Ceftriaxone, Imipenem, Levofloxacin, Meropenem, Polymyxin-B and Tetracycline (Bioanalyse- Turkey). This test was done by transferring a sufficient amount from a pure culture of the isolates into a tube of normal saline solution with optimum concentration then streaking over the surface of the (MHA) Mueller-Hinton Agar plates. After 24 hours of incubations at 37 °C, the inhibition zone diameter was measured, and the results were classified as sensitive, intermediate, or resistant [11].

Molecular detection

DNA of bacterial *A. baumannii* used in study were extracted by (Gram-negative bacteria) according to Kits WizPrep™ DNA Mini Kit [12]. After measurement the concentration and purity of

the DNA mixed with primer for 16sRNA [13] , and desgin for bla - NDM primer (F : AACAAATTGTCAGAAGGGCGG ; R: TAGCAACAGGTTCCGGTTCT). Genomic DNA of *Acinetobacter baumannii* was used to detect the 16SrRNA, blaNDM-2 genes and that have been performed through the conventional PCR with 25µl of the PCR Master mix reaction.

Statistical analyses

Datas of currents study were analyzed by usings Chi-squares (X^2) test to compared between percentagess. A levels of significance of $\alpha=0.05$ was applied to tests. (SPSS v.23 programss used to analyze currents data.

Results and Discussions

Coronasevirus diseases2019 (COVID-19) is a recent form of respiratory problem as consequen of (SARS-CoV-2) with very broad clinical spectrum. All the sample was culture on MacConkey agar, blood agar, then diagnosis were confirmed by biochemical test with catalase positive, oxidase negative for. *A. baumannii* grow on Drigalski Lactose Agar [14]. Also result insure that the isoleted sample were *A. paumannii* with VITEK-2 system according to [15] . The results of the current study observed that the 21 (65.6%) positive covid 19 sample from 32 (16SrRNA positive) of *A. bumannii* infection. While *A. baumannii* wase identified in (20%) of sample acquired from COVIDs-19e patientse in an (ICU) in Beijings, China, durings lates(ICU) admission [16]. Compared co-infections in criticallys ill patients with or without COVID-19, also *A. baumannii* was the mosts recurrently isolated bacteria among patients admitted to intensive care units (ICUs) with different periods. Result show the coinfectd patients were more in male than female groups 16/21, 5/21 (76.2%, 23.8%) respectively (Figure 1). Thes results of this study were agreement with results of (5), who docuemeted that (COVIDs-19) patientse were diagnosed with Carbabenem-resistance *A. baumannii* (CRABs), co-infection were (66.7%) male and female (33.3%). While a study in an Iranian of COVIDs-19 patients, (58%) patients weres males and (42%i) were females, with a means age of (~ 67)years olds, (89.5%) of Covids-19 patients weres co-infected through strains of *A. baumannii*, the rest (10.5%) cases were reported as *S. aureus* [17].




Fig. (1): Distribution of *A. baumannii* infection in covid -19 patients according to gender groups.

Current study was declared that (50) *A. baumannii* isolated with MDR& XDR properties from different source in , there were 21(65.6%) isolates from sputum in COVID-19 patients out of positive isolate of 16sRNA gene, burns with percentage 19(38%), while wound isolate 5(10 %) that show in (Table-1). This result declared that the highest percentage of isolate from sputum in covid-19 patients. While not found any isolate from burn or wound in covid-19 patients with non significant differences.

Table (1): Distribution of *A. bumanii* infection according to genders and COVID-19 infection status and type of clinical samples.

Sample	COVID-19 status	Gender		Total	p-value
		Male (N=34)	Female (N=16)		
Sputum	COVID-19 -Positive	16 (76.2)	5 (23.8)	21 (100.0%)	0.8 (N.S)
	COVID-19- Negative	3 (60.0%)	2 (40.0%)	5 (100.0%)	
Burn	COVID-19- Negative	12 (63.2%)	7 (36.8%)	19 (100.0%)	-
Wound	COVID-19- Negative	3 (60.0%)	2 (40.0%)	5 (100.0%)	-
Total				50 (100.0%)	

Through the COVIDs-19 pandemic, co-infection with *A. baumannii* secondaries to SARSCoV-2 infectionse has beensreported. The studied focusing on co bacterial infection among COVID-19 cases, (16.6%) *A. baumannii* bacterial isolates were obtained from respiratory samples [18].

Antimicrobial susceptibility tests were done for all *A. baumannii* isolates from covid 19 patients (21 isolates) by using the disk diffusion method (Kirby-Bauer Method) against (7) different clinically important antimicrobials. These isolates showed different susceptibility toward antimicrobials used in this study. The susceptibility to different antimicrobials was determined depending on CLSI (2020) [19].

The result of antibiotic sensitive declared that high antibiotic resistance in Covid 19 patient co-infected with *A. baumannii* with highest rates for amikacin (95.23%), while the percentage of tetracycline resistance (90.47%).

Additionally ceftriaxone is a third-generation cephalosporin class use to treat infections produced by (G-ve) Gram negative bacilli [20]. This study showed that the resistance rate against ceftriaxone was (71.42.0%).

Also, CRABs infections in COVIDs-19-positive patients admitted to the ICU were more common compared to those that were COVIDs-19 negative (21). During the COVIDs-19 pandemics, co-infection with *A. baumannii* secondary to SARS-CoV-2 infections has been reported. Among the studied focusing on co-bacterial infection in COVID-19 cases. Result revealed that *A. baumannii* isolates had moderate resistance to Meropenem with percentage (57.1%), while the resistance to Imipenem and Levofloxacin were (23.8%). The lower percentage of resistance was recorded to polymyxin-B (9.52%). (Figure -2).




Fig. (2): Antibiotic susceptibility of *A. baumannii* strains (N=21) associated with covid-19 patients.

IMP10 (Imipenem), MEM10 (Meropenem), AK 30 (Amikacin), TET 10 (Tetracycline) LEV 5 (Levofloxacin), (CTR 30) ceftriaxone, PB 300 (polymyxin-B).

Result of [21] sample suffer from covid-19 out of 32 (64%) that have MDR and XDR which have positive 16srRNA the diagnostic gene for *A. baumannii* and 18(36%) which have negative 16SrRNA in (Figure-3).




Fig. (3): Distribution of 16SrRNA the diagnostic gene for *A. baumannii*.

Result found that the presence of *bla*NDM-2, *Tet* (B) and *bla*TEM gene with percentage 15(71.4%), 12 (57.1%) and 10 (47.6%) respectively [22], The expressions of *bla* NDM lactamases does not compromise bacterial growths and is favored over other (aMBLs) metallo beta lactamase due to the lack of fitness costs leading to its worldwide dissemination among (G-ve) Gram-negative bacteria.




Fig. (4): Antibiotic resistant gene for *A. baumannii* associated with COVID-19.

While results of gene resistant to tetracycline was 57.1% this was in accordance with [23] who mention that the second category refers to tetracycline major facilitator superfamily (MFS), efflux pump: *tet* (A) and *tet* (B). so the result declared that *tet* (B) gene was most common antibiotic in covid patient co-infected with *A. baumannii*. The highest occurrence of MDRs *A. baumannii* co-infection was documented in an Egyptian patient hospitalized with COVID-19,

susceptibles only to tigecyclines and fluoroquinolones, having resistances genes *bla*NDM-1, *bla*TEMs, and CTXi-M) [24]. Also the result found that the more common *bla*NDM-2 gene among co-infected sample with percentage 15 (71.4) for positive isolate and 6 (28.6%) for negative isolate (Figure 5).




Fig. (5): Distribution of antibiotic resistant gene *bla*NDM of *A. baumannii* in infected cases with COVID-19.

According to the study results, the prevalence of the *bla*NDM- gene is higher than results obtained by [6,25] who suggested the most powerful colonization of *A. baumannii* in patient with Covid 19. While the result of antibiotic sensitive declared that high antibiotic resistance in COVID-19 patient Co-infected with *A. baumannii* to Amikacin, and the most antibiotic effect on the bacteria Levofloxacin and Imipenem and finally the Polymyxin-B. The expressions of *bla*NDM lactamase does not compromise bacterial growths and is favored over others (MBLs) due to the absence of fitness costs leading to its worldwide dissemination among (G-ve) Gram-negative bacteria in [22].

Reference

1. Baneman E, Rana MM. Management Of Acinetobacter Infections In The Immunosuppressed Host. *Emerging Transplant Infections: Clinical Challenges And Implications*. 2020;1-19.
2. Falagas M, Karveli E, Kelesidis I, Kelesidis T. Community-Acquired Acinetobacter Infections. *European Journal Of Clinical Microbiology & Infectious Diseases*. 2007;26(12):857-68.
3. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Et Al. Diagnosis And Treatment Of Adults With Community-Acquired Pneumonia. An Official Clinical Practice Guideline Of The American Thoracic Society And Infectious Diseases Society Of America. *American Journal Of Respiratory And Critical Care Medicine*. 2019;200(7):E45-E67.
4. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Et Al. Estimates Of The Severity Of Coronavirus Disease 2019: A Model-Based Analysis. *The Lancet Infectious Diseases*. 2020;20(6):669-77.
5. Abdollahi A, Aliramezani A, Salehi M, Norouzi Shadehi M, Ghourchian S, Douraghi M. Co-Infection Of ST2IP Carbapenem-Resistant Acinetobacter Baumannii With SARS-Cov-2 In The Patients Admitted To A Tehran Tertiary Referral Hospital. *BMC Infectious Diseases*. 2021;21(1):1-7.
6. Rangel K, Chagas TPG, De-Simone SG. Acinetobacter Baumannii Infections In Times Of COVID-19 Pandemic. *Pathogens*. 2021;10(8):1006.
7. Hassanzadeh P, Motamedifar M, Hadi N. Prevalent Bacterial Infections In Intensive Care Units Of Shiraz University Of Medical Sciences Teaching Hospitals, Shiraz, Iran. *Jpn J Infect Dis*. 2009;62(4):249-53.
8. Hassan RM, Salem ST, Hassan SIM, Hegab AS, Elkholy YS. Molecular Characterization Of Carbapenem-Resistant Acinetobacter Baumannii Clinical Isolates From Egyptian Patients. *Plos One*. 2021;16(6):E0251508.
9. Çağlayan P. Determination Of Important Enzymes And Antimicrobial Resistances Of Gram-Positive Haloalkaliphilic Bacteria Isolated From Salda Lake. *Ege Journal Of Fisheries And Aquatic Sciences*. 2021;38(3):375-82.
10. Faraj MM, AL-Jobori KM, Risin MH. Evaluation Of Vitik2 System For Clinical Identification Of Candida Species And Their Antifungal Exposure Test. *Iraqi Journal Of Biotechnology*. 2020;19(1).
11. Andrzejczuk S, Kosikowska U, Chwiejczak E, Stępień-Pyśniak D, Malm A. Prevalence Of Resistance To B-Lactam Antibiotics And Bla Genes Among Commensal Haemophilus Parainfluenzae Isolates From Respiratory Microbiota In Poland. *Microorganisms*. 2019;7(10):427.
12. Al Hussein L, Maleki A, Al Marjani M. Antisense Mqsr-PNA As A Putative Target To The Eradication Of Pseudomonas Aeruginosa Persists. *New Microbes And New Infections*. 2021;41:100868.

13. Momtaz H, Seifati SM, Tavakol M. Determining The Prevalence And Detection Of The Most Prevalent Virulence Genes In *Acinetobacter Baumannii* Isolated From Hospital Infections. *International Journal Of Medical Laboratory*. 2015;2(2):87-97.
14. Ermakov V, Datchenko O, Kurlykova YA. The Production Of Selective Additives To Drigalski Lactose Agar Culture Medium. *Bulletin Samara State Agricultural Academy*. 2019.
15. Roberts LW, Forde BM, Hurst T, Ling W, Nimmo GR, Bergh H, Et Al. Genomic Surveillance, Characterisation And Intervention Of A Carbapenem-Resistant *Acinetobacter Baumannii* Outbreak In Critical Care. *Medrxiv*. 2020.
16. Yang S, Hua M, Liu X, Du C, Pu L, Xiang P, Et Al. Bacterial And Fungal Co-Infections Among COVID-19 Patients In Intensive Care Unit. *Microbes And Infection*. 2021;23(4-5):104806.
17. Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, Et Al. Evaluation Of Bacterial Co-Infections Of The Respiratory Tract In COVID-19 Patients Admitted To ICU. *BMC Infectious Diseases*. 2020;20(1):646.
18. Ramadan HK-A, Mahmoud MA, Aburahma MZ, Elkhawaga AA, El-Mokhtar MA, Sayed IM, Et Al. Predictors Of Severity And Co-Infection Resistance Profile In COVID-19 Patients: First Report From Upper Egypt. *Infection And Drug Resistance*. 2020;13:3409.
19. Guerrero DM, Perez F, Conger NG, Solomkin JS, Adams MD, Rather PN, Et Al. *Acinetobacter Baumannii*-Associated Skin And Soft Tissue Infections: Recognizing A Broadening Spectrum Of Disease. *Surgical Infections*. 2010;11(1):49-57.
20. Alanazi MQ, Al-Jeraisy MI, Salam M. Prevalence And Predictors Of Antibiotic Prescription Errors In An Emergency Department, Central Saudi Arabia. *Drug, Healthcare And Patient Safety*. 2015;7:103.
21. Cultrera R, Barozzi A, Libanore M, Marangoni E, Pora R, Quarta B, Et Al. Co-Infections In Critically Ill Patients With Or Without COVID-19: A Comparison Of Clinical Microbial Culture Findings. *International Journal Of Environmental Research And Public Health*. 2021;18(8):4358.
22. Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. *Acinetobacter Baumannii* Antibiotic Resistance Mechanisms. *Pathogens*. 2021;10(3):373.
23. Beheshti M, Ardebili A, Beheshti F, Lari AR, Siyadatpanah A, Pournajaf A, Et Al. Tetracycline Resistance Mediated By Tet Efflux Pumps In Clinical Isolates Of *Acinetobacter Baumannii*. *Revista Do Instituto De Medicina Tropical De São Paulo*. 2020;62.
24. Karruli A, Boccia F, Gagliardi M, Patauner F, Ursi MP, Sommese P, Et Al. Multidrug-Resistant Infections And Outcome Of Critically Ill Patients With Coronavirus Disease 2019: A Single Center Experience. *Microbial Drug Resistance (Larchmont, NY)*. 2021;27(9):1167-75.
25. Russo A, Gavaruzzi F, Ceccarelli G, Borrazzo C, Oliva A, Alessandri F, Et Al. Multidrug-Resistant *Acinetobacter Baumannii* Infections In COVID-19 Patients Hospitalized In Intensive Care Unit. *Infection*. 2021:1-10.